NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales. This ruling means that there ...

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease. A preliminary analysis ...

Zeposia, an ulcerative colitis medication, ran Z The Light, a direct-to-consumer campaign aimed at driving awareness, intent to ask doctors for the brand, prescriptions and brand equity. Summary of ...